Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunityBio, Inc.IBRX · Entity 3618 | Chief Accounting Officer | February 22, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunityBio, Inc.
Report date February 22, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,548 |
Reported balance
After 2026-02-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-22 · Exercise / conversion · Acquired 4,065 · Balance 117,548 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. |
| Common StockSEC Table I · non-derivative | Direct | 115,875 |
Reported balance
After 2026-02-22 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-22 · Tax withholding · Disposed 1,673 · Balance 115,875 F2: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,065 |
Reported balance
After 2026-02-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-22 · Exercise / conversion · Disposed 4,065 · Balance 4,065 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
F2: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
F3: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2026 Filed Feb 25, 2026 01:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 4,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001200637-26-000004 · wk-form4_1771981498.xml · derivative · entry 3 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,065 Underlying: Common Stock · 4,065 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 01:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 1,673 | $8.70 | $14,555.10 |
DisclosureSEC source: 0001200637-26-000004 · wk-form4_1771981498.xml · nonDerivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,875 F2 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 01:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 4,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001200637-26-000004 · wk-form4_1771981498.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:50 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 5,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001200637-26-000002 · wk-form4_1770947431.xml · derivative · entry 3 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,965 Underlying: Common Stock · 5,482 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:50 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 2,257 | $6.93 | $15,641.01 |
DisclosureSEC source: 0001200637-26-000002 · wk-form4_1770947431.xml · nonDerivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,483 F2 · price: On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:50 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 5,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001200637-26-000002 · wk-form4_1770947431.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 02:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 4,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000024 · wk-form4_1740535899.xml · derivative · entry 3 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,130 Underlying: Common Stock · 4,065 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 02:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 1,669 | $3.42 | $5,707.98 |
DisclosureSEC source: 0001326110-25-000024 · wk-form4_1740535899.xml · nonDerivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,258 F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 02:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 4,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000024 · wk-form4_1740535899.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 01:16 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001326110-25-000013 · wk-form4_1739409411.xml · derivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2035-02-10 F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 10, 2025. Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 01:16 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantRestricted Stock Units · Derivative | 16,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000013 · wk-form4_1739409411.xml · derivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,447 Underlying: Common Stock · 16,447 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 00:36 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 21,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000118 · wk-form4_1734395795.xml · derivative · entry 3 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,031 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs vested as follows: 1/3rd of the RSUs subject to the award vested June 15, 2023, 1/3rd of the RSUs subject to the award vested December 15, 2023, and 1/3rd of the RSUs subject to the award vested December 15, 2024 such that the award was fully vested on December 15, 2024. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs vested as follows: 1/3rd of the RSUs subject to the award vested June 15, 2023, 1/3rd of the RSUs subject to the award vested December 15, 2023, and 1/3rd of the RSUs subject to the award vested December 15, 2024 such that the award was fully vested on December 15, 2024. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 00:36 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 7,503 | $2.87 | $21,533.61 |
DisclosureSEC source: 0001326110-24-000118 · wk-form4_1734395795.xml · nonDerivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,862 F1 · price: On December 15, 2024, the Reporting Person's restricted stock units ("RSUs") vested. The closing price of Immunity Bio, Inc.'s common stock on December 13, 2024 was the settlement price used to calculate the shares withheld. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 00:36 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 21,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000118 · wk-form4_1734395795.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:41 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 42,439 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001326110-24-000027 · wk-form4_1708983684.xml · derivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,439 Underlying: Common Stock · 42,439 shares Expires 2034-02-22 F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 22, 2024. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:41 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantRestricted Stock Units · Derivative | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000027 · wk-form4_1708983684.xml · derivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,195 Underlying: Common Stock · 12,195 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:32 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 32,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000013 · wk-form4_1706920344.xml · derivative · entry 3 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:32 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 13,470 | $3.36 | $45,259.20 |
DisclosureSEC source: 0001326110-24-000013 · wk-form4_1706920344.xml · nonDerivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,334 Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:32 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 32,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000013 · wk-form4_1706920344.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:41 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 21,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000149 · wk-form4_1703022089.xml · derivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,031 Underlying: Common Stock · 21,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:41 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 21,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000149 · wk-form4_1703022089.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:40 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 32,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000114 · wk-form4_1694043604.xml · derivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,872 Underlying: Common Stock · 32,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:40 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 32,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000114 · wk-form4_1694043604.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 01:00 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantRestricted Stock Units · Derivative | 65,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000107 · wk-form4_1693270788.xml · derivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,744 Underlying: Common Stock · 65,744 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award shall vest on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award shall vest on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:45 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 21,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000092 · wk-form4_1686951925.xml · derivative · entry 2 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,061 Underlying: Common Stock · 21,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:45 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 21,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000092 · wk-form4_1686951925.xml · nonDerivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Read SEC document |
| March 23, 2022 Filed Mar 26, 2022 01:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 14,286 | $0.00 Strike: $5.83 | $0.00 |
DisclosureSEC source: 0001326110-22-000019 · wf-form4_164825666622908.xml · derivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,286 Underlying: Common Stock · 14,286 shares Expires 2032-03-23 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is March 23, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:19 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantRestricted Stock Units · Derivative | 63,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-21-000013 · wf-form4_163977956488133.xml · derivative · entry 1 LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,091 Underlying: Common Stock · 63,091 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.